Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Anthracycline
66%
Cardiotoxicity
66%
Interstitial Lung Disease
66%
Cardiac Troponin
42%
Troponin I
42%
Heart Left Ventricle Ejection Fraction
42%
Beta Adrenergic Receptor Blocking Agent
42%
Randomized Controlled Trial
33%
Receptor Blocking
33%
Angiotensin Receptor
33%
Troponin
33%
Bone Density
33%
Teriparatide
33%
Zoledronic Acid
33%
Osteogenesis Imperfecta
33%
Heart Left Ventricle Failure
18%
Carvedilol
17%
Candesartan
17%
Breast Cancer
17%
Heart Protection
16%
Disease Course
16%
Renin-Angiotensin System Inhibitor
13%
Quality of Life
11%
Parathyroid Hormone
11%
Clinical Feature
11%
Multiple Fracture
11%
Biochemical Marker
11%
Dentinogenesis Imperfecta
11%
Patient Referral
11%
Genetic Epidemiology
11%
Sclera
11%
Summarized Data
11%
Bone Turnover
11%
Bisphosphonate
11%
Orphan Disorder
11%
Heart Muscle Injury
9%
Non-Hodgkin Lymphoma
8%
Cardiac Magnetic Resonance Imaging
8%
Dyspnea
5%
Lung
5%
Chronic Lung Disease
5%
Infection
5%
Oxygen Consumption
5%
Pediatrics
5%
Pulmonary Disorder
5%
Patient-Reported Outcome
5%
Pharmacology, Toxicology and Pharmaceutical Science
Anthracycline
100%
Cardiotoxicity
77%
Troponin I
76%
Chemotherapy
73%
Troponin
62%
Beta Adrenergic Receptor Blocking Agent
42%
Randomized Controlled Trial
33%
Angiotensin Receptor
33%
Parathyroid hormone[1-34]
33%
Zoledronic Acid
33%
Osteogenesis Imperfecta
33%
Breast Cancer
28%
Heart Muscle Injury
20%
Heart Left Ventricle Failure
18%
Candesartan
17%
Carvedilol
17%
Renin-Angiotensin System Inhibitor
13%
Epirubicin
11%
Diseases
11%
Multiple Fracture
11%
Biochemical Marker
11%
Bisphosphonic Acid Derivative
11%
Genetic Epidemiology
11%
Tooth Malformation
11%
Clinical Feature
11%
Parathyroid Hormone
11%
Nonhodgkin Lymphoma
8%
Malignant Neoplasm
5%
Cohort Study
5%
Iatrogenic Disease
5%
Nursing and Health Professions
Anthracycline
100%
Cardiotoxicity
77%
Troponin I
76%
Troponin
62%
Heart Left Ventricle Ejection Fraction
42%
Beta Adrenergic Receptor Blocking Agent
42%
Receptor Blocking
33%
Angiotensin Receptor
33%
Breast Cancer
28%
Heart Muscle Injury
20%
Heart Left Ventricle Failure
18%
Candesartan
17%
Carvedilol
17%
Heart Protection
16%
Renin
13%
Angiotensin
13%
Blood Sampling
11%
Epirubicin
11%
Health Care Quality
9%
Nonhodgkin Lymphoma
8%
Cardiovascular Magnetic Resonance
8%
Cohort Analysis
5%
Female Patient
5%
Cancer Therapy
5%
Iatrogenesis
5%
Malignant Neoplasm
5%